New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
11:37 EDTFTR, VMC, CVC, OTEX, TQNT, EWH, GALT, TEF, EXAS, RPRXHigh option volume stocks
High option volume stocks: RPRX EWH CVC EXAS TQNT VMC TEF OTEX FTR GALT
News For RPRX;EWH;CVC;EXAS;TQNT;VMC;TEF;OTEX;FTR;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:45 EDTTEFEU agrees to enact 'net neutrality' law, WSJ reports
Subscribe for More Information
June 29, 2015
07:49 EDTGALTGalectin Therapeutics initiates enrollment for GR-MD-02 Phase 2 clinical trial
Subscribe for More Information
June 26, 2015
13:46 EDTEXASFly Watch: Exact Sciences predicted to jump if task force update favorable
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015. The guidelines should include an assessment of Exact Sciences' (EXAS) Cologuard, an "easy to use, noninvasive colon cancer screening test." ANALYST TAKE: The USPSTF guidelines were noted as "the last binary event for Cologuard" by Jefferies and "the major overhang" for Exact Sciences by Mizuho Securities. Jefferies analyst Brandon Couillard and his team, which rate Exact Sciences a Buy with a $33 price target, see "significant upside" from a favorable outcome and said their thesis was boosted by confident comments from a "former affiliate of the USPSTF's review board." Mizuho analysts Peter Lawson and Eric Criscuolo, who rate Exact Sciences a Buy with a $35 price target, said they believe Cologuard will receive an "A" or "B" rating from the USPSTF, triggering further adoption by mandating coverage of Cologuard by private insurance. Baird defended Exact Sciences after the stock dropped 5.5% on Thursday, June 25, saying Exact Sciences' investor relations day was "bullish" in tone as the company provided a "deep dive" update on its Cologuard launch. Baird maintained its Outperform rating and $44 price target on the company. PRICE ACTION: Over the past week, shares of Exact Sciences are up more than 5% despite Thursday's 5.5% pullback. Over the last month, shares are up about 12% and over the last three months they are higher by almost 40%.
08:18 EDTEXASExact Sciences recent weakness unwarranted, says Baird
Subscribe for More Information
07:17 EDTEXASExact Sciences compelling as a platform growth company, says Canaccord
Subscribe for More Information
June 25, 2015
08:03 EDTEXASExact Sciences to host analyst and investor day with a conference call hookup
Subscribe for More Information
06:34 EDTEXASExact Sciences' Cologuard shows strong sales in Q2
Subscribe for More Information
June 24, 2015
15:41 EDTTEFVivendi increases position in Telecom Italia to 14.9%
Vivendi (VIVHY) announced that it has received 1.11B ordinary shares, or 8.24%, of Telecom Italia (TI) in exchange for 4.5% of the share capital of Telefonica Brasil (VIV), in accordance with the option given to it as part of the sale of GVT to Telefonica (TEF). Separately, Vivendi increased its ordinary shares in Telecom Italia from the recently purchased 1.9% with an additional stake of 4.76% purchased on June 22 for a total of 6.66%, representing a global cash payment of approximately EUR1B. Vivendi now owns 14.9% of Telecom Italia’s ordinary shares and has thus replaced Telefonica as the company’s largest shareholder. "This investment represents an opportunity for Vivendi... to expand in a market with significant growth prospects and a very strong appetite for quality content. Vivendi intends to support Telecom Italia over the long term," said the company.
June 22, 2015
07:53 EDTEXASExact Sciences estimates raised ahead of analyst Day at Canaccord
Canaccord raised its estimates on Exact Sciences ahead of June 26 Analyst Day. The firm cited the impact from the 160-person sales force addition from Ironwood Pharmaceuticals and pipeline opportunities beyond Cologuard for the increase. Canaccord raised its price target to $32 from $30 on Exact Sciences shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use